Sponsored Content
Pycnogenol® Effective for Managing Pediatric ADHD Without Side Effects Commonly Associated with Pharmaceuticals
14 Nov 2022New randomized trial at the University of Antwerp builds upon previous studies over two decades finding Pycnogenol® beneficial for natural ADHD symptom management
GENEVA, Switzerland – A new study delivers promising findings for parents and caregivers seeking a natural alternative to manage pediatric Attention-Deficit Hyperactivity Disorder (ADHD) behavior. Researchers found the super-antioxidant Pycnogenol® French maritime pine bark extract may be effective in managing hyperactivity and impulsivity in children aged six to twelve, without many of the adverse side effects experienced with the common therapy of methylphenidate, a prescription stimulant. The study measured observations and feedback from teachers and parents.
Characterized by developmentally inappropriate levels of hyperactivity, impulsivity, and inattention, ADHD is the most common pediatric neurocognitive behavioral disorder. This research builds on previous studies positioning Pycnogenol® as a key natural ingredient for the 2.4 million children in the U.S. diagnosed with ADHD looking to reduce hyperactivity and impulsivity without the adverse side effects that could steer some to stop typical pharmaceutical treatment.
“ADHD is a perplexing condition and treatment can be frustrating for many parents and children. Parents often feel reluctant to continue with prescription pharmaceuticals due to common side effects.” says author and renowned natural physician, Dr. Fred Pescatore. “Management of ADHD behavior is pivotal to improved school performance and self-esteem, especially during a child’s formative years. This study suggests a promising natural path option.”
The study, published in the Journal of Functional Foods, tested 88 children from ages six to twelve for ten weeks. Participants were split into three groups: placebo, methylphenidate and Pycnogenol®. The children supplemented at breakfast with either one or two capsules, depending on their weight. Those under 66 pounds supplemented with 20 mg/day of Medikinet® (methylphenidate) or 20 mg/day of Pycnogenol®. Those 66 pounds or heavier supplemented with 30 mg/day of Medikinet® (methylphenidate) or 40 mg/day of Pycnogenol®.
Teachers and parents filled out various questionnaires at baseline and after five and ten weeks, including the ADHD Rating Scale (ADHD-RS), which assesses nine inattention and nine hyperactivity/impulsivity items. Some of the criteria assessed included difficulty following instructions, difficulty organizing tasks and activities, fidgeting with hands or feet or squirming in seat and interrupting or intruding others.
After ten weeks, teachers reported the Pycnogenol® group showed:
29% decrease in overall ADHD rating scale (vs. 45% decrease with methylphenidate vs. 5% decrease with placebo), 34% decrease in hyperactivity/impulsivity (vs. 36% decrease with methylphenidate vs. 1% increase with placebo), 25% decrease in inattention (vs. 52% decrease with methylphenidate vs. 9% decrease with placebo).
After ten weeks, parents reported the Pycnogenol® group showed:
11% decrease in overall ADHD rating scale (vs. 28% decrease with methylphenidate vs. 1% increase with placebo), 12% decrease in hyperactivity/impulsivity (vs. 28% decrease with methylphenidate vs. 2% increase with placebo), 10% decrease in inattention (vs. 29% decrease with methylphenidate vs. 1% increase with placebo).
Children in the study who supplemented with the pharmaceutical showed improvement in ADHD behavior yet experienced up to five times more adverse effects than those who supplemented with Pycnogenol®. Specifically, loss of appetite and unwanted weight loss was observed with the pharmaceutical, but not with Pycnogenol®. The researchers conclude, “In pediatric ADHD and especially in the primary school environment, Pycnogenol® was proven to be a good alternative for methylphenidate for those willing to wait a few weeks for effects, a fortiori when considering its almost complete lack of adverse effects as opposed to methylphenidate.”
This research expands Pycnogenol®’s deep catalog of clinical research for cognitive support, solidifying the natural ingredient’s ability to manage ADHD behavior without disruptive side effects. A 2006 study conducted in the Department of Child Psychiatry at the University Hospital in Bratislava found that Pycnogenol® relieved hyperactivity and improved attention of children with ADHD compared to placebo. Another study, conducted in 2006, found Pycnogenol® normalizes total antioxidant status of ADHD children.
To review clinical research and additional information on Pycnogenol®, visit www.pycnogenol.com. Pycnogenol® is available in more than 1,000 dietary supplements and health products worldwide.
About Pycnogenol®
Pycnogenol® is a natural plant extract originating from the bark of the maritime pine that grows along the coast of southwest France and is found to contain a unique combination of procyanidins, bioflavonoids and phenolic acids, which offer extensive natural health benefits. The extract has been widely studied for the past 40 years and has more than 450 published studies and review articles ensuring safety and efficacy as an ingredient. Today, Pycnogenol® is available in more than 1,000 dietary supplements and health products worldwide. For more information, visit www.pycnogenol.com.
About Horphag Research
Horphag Research is the exclusive worldwide distributor for Pycnogenol® (pic-noj-en-all) brand French maritime pine bark extract. Pycnogenol® is a registered trademark of Horphag Research. For its patented ingredient, Pycnogenol®, Horphag Research has been awarded the Frost & Sullivan Excellence in Research Award, Nutraceutical Business & Technology Safety & Quality Award, SupplySide West Scientific Excellence Award and The American Botanical Council's Tyler Research Award. Horphag Research has the exclusive rights to market and sell Pycnogenol® worldwide and benefits from more than 40 years of scientific research assuring the safety and efficacy of Pycnogenol® as a dietary supplement.
Related news
Roquette at Fi Europe: Empowering people and planet via plant-based innovation [Interview]
26 Jan 2024
Presenting its latest F&B solutions under the banner of ‘Empowering healthier and more sustainable food choices’, Roquette’s appearance at the most recent edition of Fi Europe coincided with the innovative company’s 90th anniversary.
Read moreEmsland at Fi Europe 2023: Leading the field in sustainability and future-proofed food [Interview]
26 Jan 2024
Germany-headquartered Emsland is a vegetable protein and fibre pioneer responding in earnest to the food sector’s sustainability challenge, while supporting its customers to develop plant-based, clean label and nutritionally enhanced products through “...
Read moreStand out from the shelf and put Health First with Prebiotic Chicory Root Fibres
22 Jan 2024
If you are looking to differentiate from all other products on the market, then innovating with proven prebiotics should be your next New Product Development. When it comes to food and drink choices, consumers often take into consideration a manif...
Read moreSYNBALANCE ANNOUNCES ITS FIRST CAPSULE COLLECTION FOR INCLUSING HEALTH
20 Dec 2023
SynBalance, the biotics-oriented company, focused on delivering highly scientifically evidenced probiotic solutions, is proud to present THE ART OF WELL-BEING capsule collection.
Read more
Bioriginal expands the business in The Netherlands and Japan
13 Dec 2023
Bioriginal Food & Science Corp has completed two significant acquisitions that will expand the company’s global footprint in the EU and Asia.
Read moreBioriginal expands in Germany acquiring plant-based oil products company
13 Dec 2023
Bioriginal has expanded into Germany with the acquisition of Pflanzenölmühle Kroppenstedt GmbH operating as Kroppenstedter Ölmühle, a century-old, family-owned mill that specializes in the pressing of plant-based oil products from c...
Read moreBioriginal Acquires Softgel Co. To Expand Nutrition Products
13 Dec 2023
Bioriginal has expanded further into the United States with the acquisition of all the operating assets of Softgel Co. ("Softgel"), including a state-of-the-art softgel, squeeze tube and tincture manufacturing facility that specializes in enc...
Read moreACT Expands Global Presence: New Sales Office in Spain in Febuary 2024
13 Dec 2023
ACT proudly announces the inauguration of a new sales office in Spain as of 1st of February 2024. This strategic expansion marks a significant milestone in the company's global growth initiative, aiming to strengthen its foothold in the European ma...
Read moreBunge’s Beleaf™ PlantBetter: Elevating Plant-Based Alternatives to Match Dairy Butter - A breakthrough for taste, texture, and versatility on par with dairy butter
12 Dec 2023
Zaandam, The Netherlands, 20 November 2023 – Bunge, a global leader in food and agribusiness, introduces Beleaf™ PlantBetter, a ground-breaking plant-based alternative crafted to satisfy the growing demand for superior-tasting and environme...
Read moreofi's Carbon Scenario Planner wins prestigious Food Ingredients Europe Award
12 Dec 2023
ofi’s Carbon Scenario Planner (CSP), a new digital tool developed to help food and beverage manufacturers model the impact of different scenarios for reducing greenhouse gas emissions has won the 2023 Sustainability Innovation Award at Food Ingre...
Read more